Treatment Persistence with Combination Eye Drops for Glaucoma: A Longitudinal Analysis Using Japanese Medical Claims Data Authors: Kenji Kashiwagi, Miyuki Matsukawa, Rikiya Toda, Kana Okamoto, Daisaku Michikami Published: 2026 ABSTRACT AbstractIntroductionGlaucoma is a chronic progressive disease and the leading cause of blindness, particularly among older individuals. Treatment persistence with intraocular pressure (IOP)-lowering therapy is essential to avoid visual impairment, although data on persistence with combination eye-drop therapy are lacking. The objective of this study was to evaluate treatment persistence with combination eye-drop therapy in Japanese patients with glaucoma or ocular hypertension.MethodsThis longitudinal cohort study analysed anonymised insurance claims data from the DeSC database. Adults (≥ 18 years) with glaucoma or ocular hypertension who initiated IOP-lowering therapy within the same month as their diagnosis between June 2020 and May 2023 were included. The primary outcomes were: (1) treatment persistence among patients who initiated carteolol/latanoprost-based combination therapy (research question [RQ] 1); (2) persistence according to the number of bottles and active IOP-lowering ingredients (RQ2); (3) persistence according to the number of bottles of eye drops (RQ3); and (4) persistence according to concomitant use of different IOP-lowering drugs (RQ6).ResultsAmong patients who initiated carteolol/latanoprost (RQ1 cohort; n = 28,560), the 360-day persistence rates were highest with concomitant brimonidine/brinzolamide (23.0%) and lowest with ripasudil (16.5%). The median duration of persistence was longer with concomitant brimonidine or brimonidine/brinzolamide versus concomitant brinzolamide, ripasudil or dorzolamide (148 vs 130, 120 and 117 days, respectively). Persistence also increased with increasing number of active IOP-lowering ingredients (RQ2 cohort; two-bottles, n = 160,481; three-bottles, n = 48,994) but declined with increasing number of bottles of eye drops (RQ3 cohort; n = 188,676). Combination therapy with a β-blocker plus a prostaglandin F2α receptor agonist showed a trend towards having the longest persistence duration, while β-blocker plus carbonic anhydrase inhibitor regimens showed a trend towards the shortest duration (RQ6).ConclusionThese findings suggest that treatment persistence with combination eye-drop therapy in Japanese patients with glaucoma or ocular hypertension may differ depending on the IOP-lowering regimen.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40123-026-01384-3.Keywords: Eye drops, Fixed-dose combination, Glaucoma, Japan, Treatment persistence Key Summary Points Why carry out this study? Glaucoma is one of the leading causes of blindness and requires long-term treatment with intraocular pressure (IOP)-lowering medications.No studies have examined persistence rates with combination therapy among patients with glaucoma.This real-world longitudinal cohort study evaluated persistence with IOP-lowering combination therapy among Japanese patients with glaucoma or ocular hypertension. What was learned from the study? In patients who initiated carteolol/latanoprost, 360-day persistence rates were highest with concomitant brimonidine/brinzolamide and lowest with concomitant ripasudil (23.0% vs 16.5%).In all patients, treatment persistence appeared to increase with an increase in the number of active IOP-lowering ingredients and decline with an increase in the number of bottles of eye drops. Introduction Glaucoma is one of the leading causes of blindness and represents a large societal and healthcare burden, affecting an estimated 5.0% of individuals in Japan aged > 40 years [1, 2]. It accounted for 40.7% of new visual impairment certifications in 2019, an increase from 28.6% in 2015 [3, 4]. In both years, most newly certified individuals were aged ≥ 70 years [3, 4]. Reduction of the intraocular pressure (IOP) remains the only reliable and evidence-based treatment for glaucoma [5]. Many patients require more than one IOP-lowering agent to achieve and maintain target IOP, particularly after the first year of treatment [6]. Clinical guidelines emphasise the importance of achieving the maximal therapeutic effect with the fewest necessary medications to limit adverse events and preserve treatment adherence [5]. Fixed-dose combination (FDC) therapies offer similar IOP-lowering efficacy to unfixed combinations while reducing treatment complexity and cumulative preservative exposure [6]. Because glaucoma is a chronic, progressive disease that requires long-term treatment, treatment persistence (i.e. the time during which the patient fills the prescribed treatment until the first discontinuation) is important to avoid worsening of symptoms and increased healthcare costs [7]. However, persistence rates with combination IOP-lowering therapy among patients in Japan with glaucoma are not known. Although not limited to combination therapy, a large database study of newly diagnosed patients found that the persistence rate decreased from 73.2% at 3 months after treatment initiation to 60.9% at 12 months and 52.5% at 3 years [8]. Similarly, a claims-based analysis of second-line treatment reported a median persistence duration of 6 months for FDC therapies and 7 months for unfixed combinations, with only 39.0% and 41.7% of patients, respectively, remaining on treatment at 12 months [9]. A separate study of FDCs and unfixed combinations found that FDCs were associated with a significantly higher 12-month persistence rate than unfixed combinations (47.6 vs 24.9%) [10]. The main objective of this real-world, longitudinal descriptive cohort study was to evaluate treatment persistence among Japanese patients with glaucoma or ocular hypertension who were prescribed two or more bottles of combination eye-drop therapy in routine clinical conditions. Treatment persistence with FDC monotherapy (i.e. one FDC as the sole therapy) was also investigated. A descriptive study design was used to provide comprehensive information from multiple perspectives on real-world persistence rates with combination therapy under circumstances where information on combination therapy for glaucoma medications was largely unavailable. Methods Study Design This longitudinal, descriptive cohort study was conducted using anonymised insurance claims data from the DeSC database for patients diagnosed with glaucoma or ocular hypertension. Patients were identified from two data sources: the DeSC database [11], which provided Health Insurance, National Health Insurance and Advanced Elderly Medical Service System data from April 2014 to August 2023, and the IQVIA database, which included data from April 2015 to November 2023. The enrolment period spanned from June 2020 to February 2023 for DeSC data and from June 2020 to May 2023 for IQVIA data. If a patient was eligible on more than one occasion, only the earliest qualifying index date was considered within the same analysis for each research question (RQ). The study incorporated a 180-day “look-back” period before the index date to assess patient background characteristics, where the index date was defined as the date on which a diagnosis of glaucoma or ocular hypertension (excluding suspected cases) was recorded, and initiation of the target glaucoma eye drop regimen occurred within the same month. The study also included a follow-up period extending from the index date to the last available data point. This study used anonymised, pre-existing insurance claims data and did not involve the collection of new personal information or any direct interaction with patients. Therefore, it was not subject to the Ethical Guidelines for Life Science and Medical Research Involving Human Subjects in Japan, and informed consent was not required. An application for ethical review was submitted to the Research Ethics Committee of Otsuka Pharmaceutical Co., Ltd., which judged that no review was required (a notice of No Review [#001] was received). The study complied with the Act on the Protection of Personal Information (Act No. 57 of 2003, as amended) and all relevant subordinate regulations and guidelines. Patients Patients were included in the study if they met the following criteria: a diagnosis of glaucoma or ocular hypertension (International Classification of Disease, 10th revision [ICD-10] code: ICD-10 H40), excluding glaucoma included in ICD-10 codes H402, H405 (neovascular glaucoma) and H400 (primary angle closure); initiated IOP-lowering ophthalmic medications (see Supplementary Table S1 for Anatomical Therapeutic Chemical [ATC] classification codes), including FDCs and unfixed combination therapies, within the same month as the diagnosis; and were aged ≥ 18 years at the index date. Outcomes The primary outcomes of interest were: (1) treatment persistence with carteolol/latanoprost-based combination therapy (RQ1); (2) treatment persistence in relation to the number of bottles and active IOP-lowering ingredients (RQ2); (3) treatment persistence according to the number of bottles of eye drops (RQ3); and (4) treatment persistence according to the concomitant use of different IOP-lowering drugs (RQ6). Secondary outcomes were treatment persistence according to the size of the prescribing institute (RQ4), treatment persistence according to the duration of the prior first-line therapy (RQ5), and treatment persistence according to the type of β-blocker/prostaglandin F2α receptor agonist (BB/FP) FDC monotherapy (RQ7). Discontinuation and censoring definitions varied by RQ. For example, for RQ1, treatment cessation was defined as switching to a different glaucoma medication or no prescription of any target drugs for ≥ 180 days. RQ1 censoring criteria were withdrawal from insurance (e.g. due to death or job change). Full definitions of treatment discontinuation and censoring criteria for each RQ are provided in Supplementary Table S2. Statistical Analysis An initial feasibility assessment identified 68,643 eligible patients. In this assessment, the sample size according to the number of IOP-lowering drugs decreased from 66,206 and 13,553 patients for two- and three-drug combinations, respectively, to 1709 and 74 patients for four- and five-drug regimens, respectively. Therefore, the primary analyses focused on patients prescribed regimens containing up to three IOP-lowering drugs. Descriptive statistics were used throughout the analysis. Treatment persistence rates at 180, 360 and 720 days (i.e. proportion of patients with treatment persistence at each time point) and the median duration of treatment persistence (in days) were estimated using the Kaplan–Meier method. The association between the duration of the prior first-line therapy and the persistence with subsequent treatment was assessed using a Cox proportional hazards regression model, with the duration of the primary therapy used as the covariate. Adjustment for other covariates was not performed. Categorical variables were summarised using the number and proportion of patients, with two-sided 95% confidence intervals (CIs), and continuous variables were described using means, standard deviations (SDs), interquartile range and range (minimum, maximum value). No imputation was performed for missing data. All statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). Results Patient Cohorts For RQ1, 28,584 patients were identified as having a diagnosis of glaucoma or ocular hypertension during the enrolment period and had initiated carteolol/latanoprost-based combination therapy within the same month. After excluding patients aged < 18 years (n = 24), 28,560 patients were included in the analysis of the primary outcome (RQ1 cohort; Fig. 1). Patient flow diagram by CAR/LAT-based dual combination therapy concomitant agent (RQ1 cohort). aDefined as the date on which a diagnosis of glaucoma or ocular hypertension was recorded (excluding suspected cases); initiation of the target glaucoma eye-drop regimen occurred within the same month. CAR/LAT carteolol/latanoprost, RQ research question Patients included in the RQ1 cohort initiated carteolol/latanoprost-based dual combination therapy with one of five concomitant agents: brimonidine/brinzolamide (n = 13,503), dorzolamide (n = 992), brinzolamide (n = 3987), brimonidine (n = 7539) or ripasudil (n = 2539; Table 1). The cohort was evenly distributed by sex in most groups, although the proportion of female patients was slightly higher than that of male patients overall (50.6–58.4% vs 41.6–49.4%). The median age ranged from 75.0 to 77.0 years, and 56.3–66.7% of patients were aged ≥ 75 years. During the 180-day “look-back” period before the index date, the prevalence of new-onset dry eye or keratoconjunctivitis sicca was similar across the concomitant treatment groups (29.1–31.6%). Over two-thirds of patients (68.1–72.9%) were initially treated at prescribing institutes with < 20 beds. The vast majority of patients (99.1–99.7%) were treated in outpatient settings. Table 1Baseline and demographic characteristics of patients who received carteolol/latanoprost-based dual therapy according to concomitant agent (RQ1 cohort)Concomitant agentBrimonidine/brinzolamide (n = 13,503)Dorzolamide (n = 992)Brinzolamide (n = 3987)Brimonidine (n = 7539)Ripasudil (n = 2539)Sex, n (%) Male6677 (49.4)413 (41.6)1817 (45.6)3462 (45.9)1214 (47.8) Female6826 (50.6)579 (58.4)2170 (54.4)4077 (54.1)1325 (52.2)Age at index datea, years Mean ± SD73.9 ± 11.675.3 ± 10.872.7 ± 11.673.5 ± 11.673.8 ± 11.5 Median (IQR)76.0 (68.0–82.0)77.0 (70.0–82.0)75.0 (67.0–80.0)76.0 (68.0–81.0)75.0 (68.0–81.0) Range18–10318–9818–10321–10119–102Age category at index datea, n (%) ≥ 18 to < 65 years2347 (17.4)127 (12.8)798 (20.0)1379 (18.3)443 (17.4) ≥ 65 to < 75 years3113 (23.1)203 (20.5)946 (23.7)1651 (21.9)594 (23.4) ≥ 75 years8043 (59.6)662 (66.7)2243 (56.3)4509 (59.8)1502 (59.2)New-onset dry eye or keratoconjunctivitis sicca during look-back periodb, n (%)4223 (31.3)294 (29.6)1160 (29.1)2381 (31.6)781 (30.8) Dry eye3391 (25.1)248 (25.0)958 (24.0)1883 (25.0)626 (24.7) Keratoconjunctivitis sicca1146 (8.5)68 (6.9)271 (6.8)673 (8.9)204 (8.0)Active asthma during look-back periodb, n (%)435 (3.2)22 (2.2)97 (2.4)224 (3.0)72 (2.8)CVD during look-back periodb, n (%)4105 (30.4)328 (33.1)1147 (28.8)2195 (29.1)845 (33.3) Ischaemic heart disease1807 (13.4)150 (15.1)508 (12.7)996 (13.2)385 (15.2) Other types of heart disease3392 (25.1)262 (26.4)927 (23.3)1793 (23.8)692 (27.3) Heart failure2156 (16.0)163 (16.4)602 (15.1)1153 (15.3)445 (17.5) Atrioventricular and left bundle branch block129 (1.0)9 (0.9)25 (0.6)69 (0.9)27 (1.1) Acute myocardial infarction96 (0.7)9 (0.9)29 (0.7)56 (0.7)29 (1.1)Size of prescribing institute at index datea, n (%) < 20 beds9467 (70.1)706 (71.2)2860 (71.7)5493 (72.9)1728 (68.1) ≥ 20 to < 500 beds2568 (19.0)221 (22.3)824 (20.7)1573 (20.9)576 (22.7) ≥ 500 beds1467 (10.9)65 (6.6)302 (7.6)472 (6.3)235 (9.3)Hospitalisation status at index datea, n (%) Hospitalised69 (0.5)9 (0.9)13 (0.3)27 (0.4)20 (0.8) Outpatient13,434 (99.5)983 (99.1)3974 (99.7)7512 (99.6)2519 (99.2)CVD cardiovascular disease, IQR interquartile range, RQ research question, SD standard deviationaDefined as the date on which a diagnosis of glaucoma or ocular hypertension was recorded (excluding suspected cases); initiation of the target glaucoma eye-drop regimen occurred within the same monthbDefined as the 180-day period before the index date Baseline and demographic characteristics of patients who received carteolol/latanoprost-based dual therapy according to concomitant agent (RQ1 cohort) CVD cardiovascular disease, IQR interquartile range, RQ research question, SD standard deviation aDefined as the date on which a diagnosis of glaucoma or ocular hypertension was recorded (excluding suspected cases); initiation of the target glaucoma eye-drop regimen occurred within the same month bDefined as the 180-day period before the index date In the RQ1 cohort, the proportion of patients who were hospitalised during treatment ranged from 9.7% in the brinzolamide group to 12.9% in the brimonidine/brinzolamide group (Table 2). Among those hospitalised, the median duration of hospitalisation ranged from 2.0 to 5.0 days. Glaucoma surgery during treatment was recorded in 6.6% of patients in the brimonidine/brinzolamide group, 5.1% in the dorzolamide group, 4.8% in the ripasudil group, 3.6% in the brinzolamide group and 3.2% in the brimonidine group. Non-glaucoma ophthalmic surgery during treatment was also performed infrequently (3.0–4.9%) and the incidence of active asthma during treatment was 2.6–3.4%. New-onset dry eye or keratoconjunctivitis sicca complications during treatment that were not present in the prior 180 days were reported in 33.0–36.3% of patients. These complications were most often attributed to dry eye (in 27.3–29.3% of patients). Only 3.2–4.1% of patients experienced new-onset dry eye or keratoconjunctivitis sicca that was not present during the look-back period. Table 2Clinical characteristics during treatment of patients who received carteolol/latanoprost-based dual combination therapy according to concomitant agent (RQ1 cohort)Concomitant agentBrimonidine/brinzolamide (n = 13,503)Dorzolamide (n = 992)Brinzolamide (n = 3987)Brimonidine (n = 7539)Ripasudil (n = 2539)Hospitalisation, n (%)1739 (12.9)103 (10.4)385 (9.7)753 (10.0)269 (10.6)Duration of hospitalisation, days Mean ± SD9.3 ± 13.09.3 ± 15.19.2 ± 13.110.0 ± 13.79.4 ± 12.9 Median (IQR)4.0 (1.0–12.0)2.0 (1.0–11.0)5.0 (1.0–11.0)4.0 (1.0–14.0)4.0 (1.0–12.0) Range1–1321–861–1121–1251–79Glaucoma surgery, n (%)896 (6.6)51 (5.1)142 (3.6)239 (3.2)123 (4.8)Non-glaucoma ophthalmic surgery, n (%)583 (4.3)41 (4.1)128 (3.2)227 (3.0)124 (4.9)Active asthma, n (%)429 (3.2)34 (3.4)102 (2.6)228 (3.0)77 (3.0) Prescription of controller414 (3.1)32 (3.2)95 (2.4)217 (2.9)75 (3.0) Prescription of reliever70 (0.5)4 (0.4)22 (0.6)38 (0.5)9 (0.4)New-onset dry eye or keratoconjunctivitis sicca not present for 180 days prior to onset, n (%)4761 (35.3)331 (33.4)1314 (33.0)2739 (36.3)922 (36.3) Dry eye3790 (28.1)279 (28.1)1087 (27.3)2171 (28.8)745 (29.3) Keratoconjunctivitis sicca1333 (9.9)74 (7.5)301 (7.5)777 (10.3)236 (9.3)New-onset dry eye or keratoconjunctivitis sicca not present during the look-back perioda, n (%)558 (4.1)32 (3.2)146 (3.7)262 (3.5)86 (3.4) Dry eye427 (3.2)22 (2.2)111 (2.8)190 (2.5)66 (2.6) Keratoconjunctivitis sicca156 (1.2)12 (1.2)36 (0.9)83 (1.1)23 (0.9)IQR interquartile range, RQ research question, SD standard deviationaDefined as the 180-day look-back period before the index date (i.e. the date on which a diagnosis of glaucoma or ocular hypertension was recorded [excluding suspected cases]; initiation of the target glaucoma eye-drop regimen occurred in the same month) Clinical characteristics during treatment of patients who received carteolol/latanoprost-based dual combination therapy according to concomitant agent (RQ1 cohort) IQR interquartile range, RQ research question, SD standard deviation aDefined as the 180-day look-back period before the index date (i.e. the date on which a diagnosis of glaucoma or ocular hypertension was recorded [excluding suspected cases]; initiation of the target glaucoma eye-drop regimen occurred in the same month) In addition to the RQ1 cohort, the following cohorts were constructed to address other RQs. For RQ2, 160,481 patients were included in the two-bottle group and 48,994 in the three-bottle group (Supplementary Fig. S1). In the two-bottle group, 54,436 were receiving treatment with two active ingredients, 84,473 with three active ingredients and 21,572 with four active ingredients. In the three-bottle group, 10,382 were receiving treatment with three active ingredients, 28,709 with four active ingredients and 9903 with five active ingredients. The incidence of new-onset dry eye or keratoconjunctivitis sicca during the look-back period was 25.7–32.4% (Supplementary Table S3). Among patients receiving treatment with two bottles of glaucoma eye drops, the incidence of new-onset dry eye or keratoconjunctivitis sicca during treatment that was not present in the prior 180 days increased with the number of active ingredients, ranging from 29.7% in the two-active ingredient group to 33.6% in the four-active ingredient group (Supplementary Table S4). Similarly, the incidence of these complications increased with an increasing number of active ingredients among patients receiving treatment with three bottles of glaucoma eye drops, ranging from 32.5% in those receiving three active ingredients to 35.9% in those receiving five active ingredients. The RQ3 cohort comprised 188,676 patients, of whom 154,471 patients were receiving glaucoma treatment with two bottles of eye drops, 30,225 with three bottles and 3980 with four bottles (Supplementary Fig. S2). The incidence of new-onset dry eye or keratoconjunctivitis sicca during the look-back period was 25.5–27.6% (Supplementary Table S5). The incidence of new-onset dry eye or keratoconjunctivitis sicca during treatment not present in the prior 180 days was similar across groups stratified by the number of bottles of glaucoma eye drops (29.9% in the two- and four-bottle groups and 28.4% in the three-bottle group; Supplementary Table S6). For RQ4, patients were grouped by the size of the prescribing institute, with 131,967 patients being prescribed treatment at institutes with < 20 beds, 38,457 at institutes with ≥ 20 to < 500 beds and 18,235 at institutes with ≥ 500 beds (Supplementary Fig. S3). The incidence of new-onset dry eye or keratoconjunctivitis sicca during the look-back period was 24.9–29.1% (Supplementary Table S7). During treatment, the incidence of new-onset dry eye or keratoconjunctivitis sicca complications that was not present in the prior 180 days was 28.6–33.5% (Supplementary Table S8). The RQ5 cohort included 45,293 patients who were receiving second-line therapy at the index date (Supplementary Fig. S4). The incidence of new-onset dry eye or keratoconjunctivitis sicca complications during the look-back period was 29.2% (Supplementary Table S9) and during treatment, but not present in the prior 180 days, was 37.8% (Supplementary Table S10). For RQ7, the BB/FP FDC monotherapy cohort included 80,995 patients, of whom 40,866 were receiving treatment with carteolol/latanoprost, 20,988 with timolol/latanoprost, 8048 with timolol/travoprost and 11,093 with timolol/tafluprost (Supplementary Fig. S5). In this cohort, the incidence of new-onset dry eye or keratoconjunctivitis sicca during the look-back period was 17.4–23.1% (Supplementary Table S11) and during treatment, but not present in the prior 180 days, was 20.8–28.2% (Supplementary Table S12). Primary Outcomes: Treatment Persistence by Combination Therapy Carteolol/Latanoprost-Based Dual Combination Therapy (RQ1) At 180 days, the estimated treatment persistence rate with carteolol/latanoprost-based dual combination therapy varied across groups defined by concomitant agent, ranging from 37.6% with concomitant dorzolamide to 44.6% with brimonidine/brinzolamide (Fig. 2). At 360 days, treatment persistence rates had declined, being highest with concomitant brimonidine/brinzolamide (23.0%) and lowest with ripasudil (16.5%). At 720 days, persistence rates were highest with concomitant brimonidine/brinzolamide (5.8%) and lowest with ripasudil (3.1%). Kaplan–Meier curve of persistence rate on CAR/LAT-based dual therapy according to the concomitant agent (RQ1). BRIM/BRIN brimonidine/brinzolamide, CAR/LAT carteolol/latanoprost, CI confidence interval, RQ research question The median duration of treatment persistence (i.e. the time from start of treatment until 50% of patients discontinued treatment or were censored) was longest in patients receiving carteolol/latanoprost plus brimonidine/brinzolamide (148 days; 95% CI 142–154) or carteolol/latanoprost plus brimonidine (148 days; 95% CI 141–154) and shortest in those receiving carteolol/latanoprost plus dorzolamide (117 days; 95% CI 106–125). Number of Bottles and Active IOP-Lowering Ingredients (RQ2 and RQ3) Treatment persistence rates varied according to the number of bottles and number of active IOP-lowering ingredients in the prescribed glaucoma eye-drop regimen (Fig. 3). Among patients using a two-bottle regimen, persistence rates ranged from 37.7% in the two-active ingredient group to 43.1% in the four-active ingredient group at 180 days, from 18.9% to 22.4% in the respective groups at 360 days, and from 4.4% to 5.9%, respectively, at 720 days (Fig. 3a). A similar trend was observed for the median duration of persistence, which increased with the number of active ingredients from 113 days (95% CI 111–114) in the two-active ingredient group to 124 days (95% CI 122–126) and 137 days (95% CI 134–141) in the three-active and four-active ingredient groups, respectively. Kaplan–Meier curves of persistence rate according to the number of active IOP-lowering ingredients used in combination therapy with a two or b three bottles of eye drops (RQ2). CI confidence interval, IOP intraocular pressure, RQ research question Among patients using a three-bottle regimen, persistence rates also increased as the number of active ingredients increased from three to four or five active ingredients (Fig. 3b). The 180-, 360- and 720-day persistence rates were numerically higher in the four- (34.7%, 16.3% and 3.6%, respectively) and five- (34.5%, 15.9% and 3.8%, respectively) active ingredient groups than in the three-active ingredient group (30.3%, 13.3% and 3.0%, respectively). Similarly, the median duration of persistence was higher in the four-active ingredient (102 days; 95% CI 99–105) and five-active ingredient (99 days; 95% CI 94–101) groups than in the three-active ingredient group (89 days; 95% CI 85–92). Treatment persistence rates declined with increasing number of bottles of glaucoma eye drops in the prescribed regimen (RQ3; Fig. 4). At 180 days, the estimated persistence rate decreased from 45.3% in the two-bottle group to 42.3% in the three-bottle group and 35.9% in the four-bottle group. Persistence rates were 24.9%, 22.4% and 17.9% in the respective groups at 360 days and 6.8%, 6.5% and 4.6%, respectively, at 720 days. A similar trend was observed in the median duration of persistence. Patients using a two-bottle regimen had the longest median duration of persistence (151 days; 95% CI 149–154), followed by those using three bottles (134 days; 95% CI 131–138) and those using four bottles (111 days; 95% CI 105–118). Kaplan–Meier curve of persistence rate according to the number of bottles of eye drops used in combination therapy (RQ3). CI confidence interval, RQ research question Concomitant Use of Different IOP-Lowering Drugs (RQ6) When persistence rates were assessed according to the concomitant use of different IOP-lowering eye drops, the highest persistence rate at 360 days was observed in patients receiving a BB (carteolol) plus an FP (travoprost) combination (27.0%; 95% CI 23.7–30.4; n = 714), while the lowest rate was recorded with a BB (timolol) plus carbonic anhydrase inhibitor (dorzolamide) combination (11.6%; 95% CI 9.2–14.4; n = 617; Supplementary Table S13). The median duration of persistence with these drug combinations were 169 days for travoprost plus carteolol and 57 days for timolol plus dorzolamide. Secondary Outcomes: Treatment Persistence by Other Factors Size of Prescribing Institute (RQ4) The treatment persistence rate was lower among patients who were treated at larger prescribing institutes (Fig. 5). In the < 20-, ≥ 20 to < 500- and ≥ 500-bed groups, persistence rates were 40.8%, 39.1% and 34.7%, respectively, at 180 days, 20.5%, 20.1% and 17.2%, respectively, at 360 days and 5.1%, 4.9% and 3.8%, respectively, at 720 days. The median duration of persistence followed a similar pattern. The median duration of persistence was 127 days (95% CI 126–127) in patients who were prescribed treatment at institutes with < 20 beds, 120 days (95% CI 119–120) in those at institutes with ≥ 20 to < 500 beds and 95 days (95% CI 92–99) in those treated at institutes with ≥ 500 beds. Of note, the rate of glaucoma surgery during the treatment period increased with the size of the prescribing institute (Supplementary Table S8). Kaplan–Meier curve of persistence rate according to the size of the prescribing institute (RQ4). CI confidence interval, RQ research question Duration of First-Line IOP-Lowering Therapy (RQ5) Among patients who were receiving second-line therapy at the index date (n = 45,293), the persistence rate (95% CI) at 180, 360 and 720 days was 41.1% (40.7–41.6), 21.3% (21.0–21.7) and 5.3% (5.1–5.5), respectively (Supplementary Fig. S6). The median duration of persistence for first-line IOP-lowering therapy was 127 days. In the Cox proportional regression analysis, a longer duration of first-line therapy was significantly associated with increased persistence with second-line combination therapy (Table 3). This corresponded to a 2.8% reduction in the risk of discontinuation for each additional year of prior treatment. Table 3Cox proportional regression analysis of factors associated with persistence with second-line IOP-lowering therapy (RQ5)Maximum likelihood estimate ± SEHRP-valueaDuration of first-line therapy, per year− 0.0281 ± 0.00320.9723< 0.0001HR hazard ratio, IOP intraocular pressure, RQ research question, SE standard erroraCalculated using the Wald test Cox proportional regression analysis of factors associated with persistence with second-line IOP-lowering therapy (RQ5) HR hazard ratio, IOP intraocular pressure, RQ research question, SE standard error aCalculated using the Wald test Type of BB/FP FDC Monotherapy (RQ7) Among patients receiving monotherapy with selected BB/FP FDCs (n = 80,995), persistence rates were similar across all groups at 180 days, ranging from 53.0% with timolol/latanoprost to 54.4% with timolol/tafluprost (Supplementary Fig. S7). Persistence rates ranged from 32.5% with timolol/latanoprost to 34.3% with timolol/tafluprost at 360 days, and from 9.6% with carteolol/latanoprost to 10.8% with timolol/tafluprost at 720 days. The median duration of persistence ranged from 202 days (95% CI 196–208) with timolol/latanoprost to 212 days (95% CI 204–222) with timolol/tafluprost. Discussion This large, descriptive cohort study examined real-world treatment patterns and persistence among Japanese patients with glaucoma or ocular hypertension who were receiving combination therapy with IOP-lowering eye drops, including older patients (aged ≥ 65 years), who are known to have a high prevalence of glaucoma [12]. Treatment selection and persistence may be strongly influenced by clinical factors that cannot be measured in routine practice. However, considering the absence of data for key clinical variables relevant to glaucoma management (disease severity, IOP, visual field status), the aim of this study was to examine the relationship between treatment persistence and concomitant use patterns, rather than treatment efficacy and safety. The 360-day persistence rate for these regimens was low (10–30%) and seemed to differ according to treatment regimen, number of bottles and active IOP-lowering ingredients in the regimen, the size of the prescribing institute and the prior duration of first-line treatment. The analysis of carteolol/latanoprost-based combinations (RQ1) showed greater 360-day rates of persistence when brimonidine/brinzolamide (23.0%), brimonidine (21.1%) or brinzolamide (21.0%) was the concomitant agent rather than dorzolamide (17.7%) or ripasudil (16.5%). One possible explanation for this observation is that, because of the descriptive nature of this study, differences in patient characteristics between groups may have influenced the results. For example, brimonidine is often prescribed in patients with normal-tension glaucoma, which has a high prevalence among Japanese populations [13], and for whom tolerability is prioritised over maximum IOP reduction [14, 15]. Furthermore, in patients with normal-tension glaucoma, the rate of progression of glaucomatous optic nerve damage (IOP reduction) tends to be slower, resulting in a longer time required to achieve the desired therapeutic effect, which may in turn contribute to prolonged persistence. Of note, information on disease type, IOP and disease severity was not available in the database used in this study; therefore, further studies using data sources that include these clinical parameters are needed. Brinzolamide also has a favourable safety profile and is administered twice daily [14], compared with three times daily for dorzolamide [16], which may possibly relate to improved persistence and may explain the longer persistence observed with brinzolamide in this study. Furthermore, brimonidine/brinzolamide was the only FDC assessed as a concomitant agent for RQ1. Patients receiving carteolol/latanoprost plus brimonidine/brinzolamide (i.e. four active IOP-lowering ingredients in two bottles of eye drops) may have had a higher persistence rate than those receiving single-ingredient concomitant agents because of better target IOP achievement, which is consistent with the findings of the RQ2 cohort. Persistence rates at 360 days tended to be higher in this study when a BB plus an FP were used in combination than when a BB plus a carbonic anhydrase inhibitor were combined (RQ6). FPs have a large IOP-lowering effect [17] and are widely used for the first-line treatment of glaucoma or intraocular hypertension [5]. Similarly, BBs are often used as first-line or second-line treatment, although they have inferior IOP-lowering efficacy to that of FPs [18]. In analyses of persistence rates by the number of bottles of eye drops and active IOP-lowering ingredients (RQ2), regimens with more active ingredients were associated with greater 360-day persistence rates. This may be related not only to treatment intensity, but also to the treatment of patients with more advanced disease or those under closer clinical monitoring. However, increased treatment intensity has also been linked to higher rates of corneal disorders [19], underscoring the need for individualised treatment planning and regular monitoring of tolerability and efficacy. By contrast, an increased number of bottles of eye drops (RQ3) was associated with lower 360-day persistence rates. This finding is also consistent with a previous study [9]. Increasing the number of bottles likely increases the treatment burden and reduces persistence, especially in older patients or those with reduced manual dexterity or cognitive capacity. In addition, the use of multiple bottles of eye drops may increase exposure to preservatives, such as benzalkonium chloride, potentially contributing to ocular surface toxicity and treatment discontinuation [20]. However, the incidence of new-onset dry eye or keratoconjunctivitis sicca during treatment did not increase as the number of bottles increased in this study. Taken together, the findings from the RQ2 and RQ3 analyses support the clinical rationale for using FDC therapies, which allow the delivery of multiple active IOP-lowering ingredients in a single bottle and have been associated with improved treatment adherence [10]. In the analysis by institute size, 360-day persistence rates decreased as the size of the prescribing institute increased (RQ4). These findings are similar to those of a previous Japanese database study [8] and may reflect the fact that severely ill patients are more likely to attend larger facilities, particularly those with surgical capacity, where it is more likely that treatment will be reviewed. The high number of glaucoma surgeries performed at large institutes during follow-up supports this interpretation. A longer duration of prior first-line treatment was significantly associated with persistence on second-line combination therapy (RQ5). This finding is also consistent with that of a previous Japanese database study [9] and may indicate a more gradual disease course or better treatment engagement among patients with longer first-line treatment durations. The duration of first-line treatment may thus serve as a useful proxy for long-term treatment behaviour, with shorter persistence potentially identifying patients at higher risk of early discontinuation who need closer follow-up and counselling. Overall, the 360-day persistence rates observed in this study were in line with previous reports, which have varied widely but generally confirm suboptimal persistence in real-world glaucoma care [21]. A systematic review reported an average 1-year persistence rate of 31%, ranging from 10 to 68% across studies [21]. Importantly, our study focused specifically on combination therapy with multiple agents, which may partly explain the relatively low persistence rates we observed. Importantly, poor persistence with IOP-lowering medications has been linked to worse disease outcomes in patients with glaucoma, and improving persistence remains a critical target for clinical intervention [22]. Strategies to support treatment persistence may include simplification of treatment regimens through the use of FDCs and regular monitoring of IOP and treatment tolerability. Increased health literacy among patients with glaucoma [23], as well as early support for individuals who tend to show low rates of persistence, may also help to improve treatment persistence in this setting. Lastly, we examined a subpopulation of patients who received monotherapy with a BB/FP FDC (RQ7), which is contraindicated in patients with asthma. Notably, active asthma was reported in 2.6–3.3% of patients in the RQ7 cohort during the look-back period and in 3.0–3.6% during treatment with the BB/FP FDC, with 2.9–3.4% being prescribed controlled therapy and 0.5–0.6% being prescribed reliever therapy during follow-up. This suggests that contraindicated use of BB/FP FDC monotherapy did occur. These rates of contraindicated use are similar to those reported in a previous cohort study (3.3%) [24] and indicate a need for heightened awareness of contraindications when prescribing BB-containing combinations. This study has several limitations that should be considered when interpreting the study findings. First, because of the descriptive nature of this study, there was no adjustment for confounding factors. As a result, causal relationships between treatment persistence and the variables examined, such as the number of ingredients and bottles used, could not be established and the findings should be interpreted with caution. Second, considering the lack of key clinical variables relevant to glaucoma management, such as glaucoma severity, IOP measurements, glaucoma subtype, disease duration, and the laterality and exact dosing of eye-drop administration, the study was limited to examining the relationship between treatment persistence and concomitant use patterns. Similarly, the data sources did not capture the underlying reasons for treatment discontinuation or allow for precise classification of glaucoma subtypes. Lastly, the use of claims data may have introduced potential biases related to the population covered, as the data primarily reflect insured individuals associated with large corporations and their families, which may not be representative of the broader Japanese population. In addition, while a 180-day look-back period was applied to reduce duplication, it was not possible to track patients across insurance transitions. For example, when individuals reach 75 years of age, they become eligible for different coverage, which raises the possibility that some patients may have been counted more than once. Conclusion In this longitudinal cohort study, treatment persistence with combination eye-drop therapy in Japanese patients with glaucoma or ocular hypertension seemed to differ depending on the IOP-lowering treatment regimen, with persistence rates of 10–30% after approximately 1 year of treatment. While there are many possible reasons for treatment discontinuation, including the use of BBs in patients with asthma, these findings underscore the importance of considering the expected persistence rates when selecting IOP-lowering agents and supports the use of strategies to improve treatment persistence. In particular, the use of FDC ophthalmic solutions may help reduce treatment burden and support long-term treatment persistence, which is essential for achieving optimal outcomes in chronic glaucoma management. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 681 KB) Acknowledgments Medical Writing, Editorial, and Other Assistance We would like to thank Georgii Filatov, who assisted in preparing the outline of the manuscript on behalf of Springer Health+, Sarah Greig, PhD, CMPP, of Springer Health+, who assisted in preparing the subsequent drafts, and Carmen Innes, CMPP, of Springer Health+, who assisted with post-submission revisions. This medical writing assistance was funded by Otsuka Pharmaceutical Co., Ltd. Hiroe Takeda (an employee of Otsuka Pharmaceutical Co., Ltd.) provided assistance with the design of the study. Statistical analyses were supported by EPS Corporation (Tokyo, Japan). Author Contributions Conceptualization: Kenji Kashiwagi, Miyuki Matsukawa, Rikiya Toda, Kana Okamoto, Daisaku Michikami. Methodology: Kenji Kashiwagi, Miyuki Matsukawa, Rikiya Toda, Kana Okamoto, Daisaku Michikami. Formal analysis and investigation: Kenji Kashiwagi, Miyuki Matsukawa, Rikiya Toda, Kana Okamoto, Daisaku Michikami. Writing—original draft preparation: Kenji Kashiwagi, Miyuki Matsukawa, Rikiya Toda, Kana Okamoto, Daisaku Michikami. Writing—review and editing: Kenji Kashiwagi, Miyuki Matsukawa, Rikiya Toda, Kana Okamoto, Daisaku Michikami. Funding This study, development of the manuscript and the journal’s Rapid Service Fee were supported by Otsuka Pharmaceutical Co., Ltd. Data Availability The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Conflict of Interest Kenji Kashiwagi reports receiving consulting fees from Otsuka Pharmaceutical Co., Ltd., Novartis, Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd. and Kowa Company, Ltd. Miyuki Matsukawa, Rikiya Toda, Kana Okamoto and Daisaku Michikami are employees of Otsuka Pharmaceutical Co., Ltd. Ethical Approval This study used anonymised, pre-existing insurance claims data and did not involve the collection of new personal information or any direct interaction with patients. As such, it was not subject to the Ethical Guidelines for Life Science and Medical Research Involving Human Subjects in Japan, and informed consent was not required. An application for ethical review was submitted to the Research Ethics Committee of Otsuka Pharmaceutical Co., Ltd., which judged that no review was required (a notice of No Review [#001] was received). The study complied with the Act on the Protection of Personal Information (Act No. 57 of 2003, as amended) and all relevant subordinate regulations and guidelines. References Associated Data Supplementary Materials Supplementary file1 (DOCX 681 KB) Data Availability Statement The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.